A recent publication by Dr. Bertoni in collaboration with Prof. Luca Aresu of the Department of Veterinary Sciences from the University of Turin has paved the way to a new approach in biomedical research, highlighting the importance of the use of the dog as comparative and pre-clinical model in oncology medicine. Authors provide brand new data on transcriptomic, methylation and chromosomal rearrangements profiles of the canine Diffuse large B-cell lymphoma (DLBCL). This research holds the promise of improving treatment for both species. Target pathways, such as MYC, PI3K and NF-kB, have been identified showing similarity to the human DLBCL. Also, the authors have identified differences that should be considered in future clinical trials. One of the most intriguing results is related to the expression of a T-cell-related signature that affects the outcome of the dogs with DLBCL, including PD-1, PDL-1 and CTLA-4 genes. Definitely, the intact immune system in dogs developing spontaneous tumors will represent in the future an appealing element when working in comparative medicine.